Pharmacovigilance, 2nd Edition
A Practical Approach
Date of Publication: 02/2025
This item will be released on 28/02/2025. Pre-order now and we will deliver on the release date.
Written by multidisciplinary experts in the fields of pharmaceutical and patient safety, Pharmacovigilance: A Practical Approach, 2nd Edition, provides a succinct, easy-to-digest overview of an increasingly critical area of medical safety. From cover to cover, this concise resource offers essential information for physicians and other health care professionals, clinical researchers, and regulators who need a comprehensive, up-to-date source of information on the principles and practice of pharmacovigilance.
Written by multidisciplinary experts in the fields of pharmaceutical and patient safety, Pharmacovigilance: A Practical Approach, 2nd Edition, provides a succinct, easy-to-digest overview of an increasingly critical area of medical safety. From cover to cover, this concise resource offers essential information for physicians and other health care professionals, clinical researchers, and regulators who need a comprehensive, up-to-date source of information on the principles and practice of pharmacovigilance.
New to this edition
·Re-organized and expanded with 3 new sections and 9 new chapters covering pre-clinical safety assessment, pharmacogenetics, first-in human trials, product aggregate safety assessment, and data monitoring committees.·Up-to-date coverage of hot topics in the field, including pharmacodynamic and safety precision medicine, immunogenicity, vaccine hesitancy and safety, genetic toxicology, and adverse events.
Key Features
- Presents vital, easy-to-read, cutting-edge information on patient safety, the pharmacology regulatory landscape, and the current and future use of digital technologies.
- Provides up-to-date coverage of hot topics in the field, including pharmacodynamic and safety precision medicine, immunogenicity, vaccine hesitancy and safety, genetic toxicology, and adverse events.
- Contains new chapters on pre-clinical safety assessment, pharmacogenetics, first-in human trials, product aggregate safety assessment, data monitoring committees, and more.
- Offers new and expanded coverage of pharmacovigilance in early pre-clinical drug development through post-marketing surveillance, as well as a blueprint for training future pharmacovigilance professionals.
- Includes real-world case studies to ensure content is relevant and applicable to everyday practice.
- Discusses a range of topics across disciplines and how they relate to pharmacovigilance, including behavioral science, patient perspectives, and risk communication.
- An eBook version is included with purchase. The eBook allows you to access all of the text, figures and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud. Additional digital ancillary content may publish up to 6 weeks following the publication date.
Author Information
Edited by Thao Doan, MD, Sr. Medical Director, Medical Safety Evaluation, AbbVie Inc., Chicago. IL; Fabio Lievano, MD, Vice President, Safety Sciences, Medical Safety Evaluation Pharmacovigilance and Patient Safety, AbbVie Inc., Chicago. IL; Linda Scarazzini, MD, Vice President, Pharmacovigilance and Patient Safety, AbbVie Inc., Chicago. IL; Charles Schubert and Barbara Hendrickson
